Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 238

1.

Imatinib mesylate (STI571) for myeloid malignancies other than CML.

Krystal GW.

Leuk Res. 2004 May;28 Suppl 1:S53-9. Review.

PMID:
15036942
[PubMed - indexed for MEDLINE]
2.

Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.

Cortes J, Kantarjian H.

Cancer. 2004 May 15;100(10):2064-78. Review.

PMID:
15139047
[PubMed - indexed for MEDLINE]
Free Article
3.

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.

Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H.

Cancer. 2003 Jun 1;97(11):2760-6.

PMID:
12767088
[PubMed - indexed for MEDLINE]
Free Article
4.

Imatinib mesylate in the treatment of hematologic malignancies.

Piccaluga PP, Rondoni M, Paolini S, Rosti G, Martinelli G, Baccarani M.

Expert Opin Biol Ther. 2007 Oct;7(10):1597-611. Review.

PMID:
17916051
[PubMed - indexed for MEDLINE]
5.

Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.

Pardanani A, Tefferi A.

Blood. 2004 Oct 1;104(7):1931-9. Epub 2004 May 27. Review.

PMID:
15166033
[PubMed - indexed for MEDLINE]
Free Article
6.

Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.

Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17456-61. Epub 2004 Oct 25.

PMID:
15505216
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

[Imatinib].

Urabe A.

Gan To Kagaku Ryoho. 2003 Aug;30(8):1191-6. Review. Japanese.

PMID:
12938280
[PubMed - indexed for MEDLINE]
8.

Pharmacology of imatinib (STI571).

Buchdunger E, O'Reilly T, Wood J.

Eur J Cancer. 2002 Sep;38 Suppl 5:S28-36. Review.

PMID:
12528770
[PubMed - indexed for MEDLINE]
9.

Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.

Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.

Gynecol Oncol. 2004 Oct;95(1):32-6.

PMID:
15385107
[PubMed - indexed for MEDLINE]
10.

[Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].

Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.

Ai Zheng. 2004 Dec;23(12):1696-9. Chinese.

PMID:
15601563
[PubMed - indexed for MEDLINE]
11.

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.

Giles FJ, Cortes JE, Kantarjian HM.

Curr Mol Med. 2005 Nov;5(7):615-23. Review.

PMID:
16305488
[PubMed - indexed for MEDLINE]
12.

Targeted chronic myeloid leukemia therapy: seeking a cure.

Fausel C.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. Review.

PMID:
17970609
[PubMed - indexed for MEDLINE]
Free Article
13.

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.

Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ.

Cancer Chemother Pharmacol. 2003 Sep;52(3):229-34. Epub 2003 May 29.

PMID:
12783207
[PubMed - indexed for MEDLINE]
14.

Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.

Haberler C, Gelpi E, Marosi C, Rössler K, Birner P, Budka H, Hainfellner JA.

J Neurooncol. 2006 Jan;76(2):105-9.

PMID:
16205964
[PubMed - indexed for MEDLINE]
15.

[Imatinib and solid tumours].

Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.

Bull Cancer. 2008 Jan;95(1):99-106. doi: 10.1684/bdc.2008.0557. Review. French.

PMID:
18230575
[PubMed - indexed for MEDLINE]
16.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
[PubMed - indexed for MEDLINE]
17.

The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.

Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM.

Biochem Pharmacol. 2009 Feb 1;77(3):310-21. doi: 10.1016/j.bcp.2008.10.008. Epub 2008 Oct 30.

PMID:
19014913
[PubMed - indexed for MEDLINE]
18.

Imatinib: a targeted clinical drug development.

Capdeville R, Silberman S.

Semin Hematol. 2003 Apr;40(2 Suppl 2):15-20. Review.

PMID:
12783370
[PubMed - indexed for MEDLINE]
19.

Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis.

Agis H, Sotlar K, Valent P, Horny HP.

Leuk Res. 2005 Oct;29(10):1227-32.

PMID:
16111540
[PubMed - indexed for MEDLINE]
20.

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.

Konig H, Holyoake TL, Bhatia R.

Blood. 2008 Feb 15;111(4):2329-38. Epub 2007 Dec 4.

PMID:
18056843
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk